T. Rowe Price Associates’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-123,291
| Closed | -$2.82M | – | 3059 |
|
|
2024
Q4 | $2.82M | Buy |
+123,291
| New | +$2.82M | ﹤0.01% | 1477 |
|
|
2022
Q4 | – | Sell |
-1,015
| Closed | -$13K | – | 2963 |
|
|
2022
Q3 | $13K | Hold |
1,015
| – | – | ﹤0.01% | 2928 |
|
|
2022
Q2 | $21K | Sell |
1,015
-157
| -13% | -$3.25K | ﹤0.01% | 2919 |
|
|
2022
Q1 | $44K | Buy |
1,172
+370
| +46% | +$13.9K | ﹤0.01% | 2926 |
|
|
2021
Q4 | $77K | Sell |
802
-5
| -0.6% | -$480 | ﹤0.01% | 2896 |
|
|
2021
Q3 | $117K | Sell |
807
-970
| -55% | -$141K | ﹤0.01% | 2814 |
|
|
2021
Q2 | $328K | Buy |
1,777
+247
| +16% | +$45.6K | ﹤0.01% | 2553 |
|
|
2021
Q1 | $377K | Buy |
1,530
+526
| +52% | +$130K | ﹤0.01% | 2482 |
|
|
2020
Q4 | $283K | Buy |
1,004
+337
| +51% | +$95K | ﹤0.01% | 2440 |
|
|
2020
Q3 | $160K | Buy |
+667
| New | +$160K | ﹤0.01% | 2462 |
|
|
2019
Q4 | – | Sell |
-20,196
| Closed | -$1.15M | – | 2537 |
|
|
2019
Q3 | $1.15M | Buy |
+20,196
| New | +$1.15M | ﹤0.01% | 1750 |
|
|
2018
Q3 | – | Sell |
-67,500
| Closed | -$3.58M | – | 2582 |
|
|
2018
Q2 | $3.58M | Sell |
67,500
-119,250
| -64% | -$6.32M | ﹤0.01% | 1481 |
|
|
2018
Q1 | $52.6M | Buy |
186,750
+17,993
| +11% | +$5.07M | 0.01% | 849 |
|
|
2017
Q4 | $39.7M | Sell |
168,757
-25
| -0% | -$5.88K | 0.01% | 950 |
|
|
2017
Q3 | $47.9M | Sell |
168,782
-35
| -0% | -$9.93K | 0.01% | 857 |
|
|
2017
Q2 | $47.5M | Sell |
168,817
-35
| -0% | -$9.85K | 0.01% | 842 |
|
|
2017
Q1 | $56.4M | Sell |
168,852
-1,168
| -0.7% | -$390K | 0.01% | 779 |
|
|
2016
Q4 | $56.1M | Buy |
170,020
+7,052
| +4% | +$2.33M | 0.01% | 774 |
|
|
2016
Q3 | $43.5M | Buy |
+162,968
| New | +$43.5M | 0.01% | 856 |
|